Trevi Therapeutics, Inc. TRVI Payments Of Stock Issuance Costs
Payments Of Stock Issuance Costs at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.
The official record: Trevi Therapeutics, Inc.’s 10-K, filed March 17, 2026, on SEC EDGAR. View the filing →
Ask your AI about Trevi Therapeutics, Inc.'s payments of stock issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Trevi Therapeutics, Inc.'s payments of stock issuance costs?
- Trevi Therapeutics, Inc. (TRVI) reported payments of stock issuance costs of $0 in Q4 2025.
- What is the long-term trend for Trevi Therapeutics, Inc.'s payments of stock issuance costs?
- Over 3 years (2021 to 2025), Trevi Therapeutics, Inc.'s payments of stock issuance costs has grown at a 24.4% compound annual growth rate (CAGR), from $420K to $809K.
- What does payments of stock issuance costs mean?
- This represents the cash outflows incurred for professional fees, registration expenses, and other costs directly attributable to the issuance of equity securities. These costs are deducted from the gross proceeds of an offering to determine the net capital raised. Monitoring these payments helps assess the efficiency of the company's capital-raising activities and the impact of transaction-related expenses on net cash flow.